Dec.29 — China is expanding its generic drug-procurement program to include an additional 33 drugs, pitting domestic and international drugmakers in a price war that could see Chinese players dominate. Meanwhile, a newly approved Chinese drug for Alzheimer’s will start clinical trials in the U.S. and Europe next year as the country’s first novel therapy for the incurable disease seeks global legitimacy. Rachel Chang reports on “Bloomberg Markets: China Open.” …read more
Source:: Yahoo Finance
